Open company graph database — free web & API
Login

Asuka Pharmaceutical Medical Inc.

株式会社あすか製薬メディカルASKA Pharmaceutical Co., Ltd.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
635
Related companies
5
§01

Basic information

BASIC
Head office
2-5-1 Shibaura, Minato-ku, Tokyo 108-8532, Japan
Chief executive
Soichi Yamaguchi
Capital
1,197,900,000  (11 100 million)
Employees (non-consolidated)
643 people
Employees (consolidated)
635 people
Start date
1929-06-28
End date
§02

Websites

1 DOMAINS
§03

Business

13
Import and exportPharmaceuticalsQuasi-drugsFood productsManufacture and sale of medical devices, etc.Development and sale of dysmenorrhea treatmentsDevelopment and sale of oral contraceptivesResearch and developmentDrug discovery research recruitmentPipeline and intellectual property strategyProductionMedical information provision activitiesReliability assurance
§04

Related companies

5 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Asuka Animal Health Co., Ltd.
Group
Asuka Pharmaceutical Holdings Inc.
Group
Hà Tây Pharmaceutical Joint Stock Company
Group
Omnicare Drugs India Privare Limited
Alliance
NeoASKA Pharma Private Limited
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

48 EVENTS

Founded by Yashiro Yamaguchi, established theSources

Launched male gonadal hormone preparation "Spermatin"Sources

Launched hypothyroidism treatment drug "Thyrazin"Sources

Reorganized into a corporation "Imperial Organ Medicine Research Institute"Sources

Established Takatsu Factory in Takatsu Town, Tachigi District, Kanagawa Prefecture (Kawasaki City)Sources

Changed company name to "Imperial Organ Pharmaceutical Co., Ltd."Sources

Relocated headquarters to Minato Ward, Tokyo, Shiba Minami Sakuragaoka (Nishi-Shimbashi, Minato Ward)Sources

Eiichi Yamaguchi assumes the position of PresidentSources

Listed on the Tokyo Stock ExchangeSources

Started manufacturing and selling veterinary medicinesSources

Relocated headquarters to Akasaka, Minato WardSources

Started clinical testing businessSources

Started medical equipment businessSources

Established Iwaki Factory in Iwaki City, Fukushima PrefectureSources

Launched prostate treatment drug "Prostal Tablets" (added indication for prostate cancer in May 1983)Sources

Launched gastric ulcer treatment drug "Altat Capsule" (added indication for gastritis in June 1993)Sources

Established subsidiary "Medical System Service Corporation Kanagawa (currently Asuka Pharmaceutical Medical)"Sources

Takahiro Yamaguchi assumes the position of PresidentSources

Opened international resident office in Frankfurt, GermanySources

Launched oral contraceptive "Anju"Sources

Celebrated 80th anniversarySources

Built and relocated headquarters building to Shibaura, Minato WardSources

Launched hyperlipidemia treatment drug "Lipidil Capsule"Sources

Merged with Grelane Pharmaceutical Co., Ltd., changed company name to "Asuka Pharmaceutical Co., Ltd."Sources

Launched emergency contraceptive "Norlevo Tablets"Sources

Launched hyperlipidemia treatment drug "Lipdil Tablets"Sources

Completed Iwaki Factory and Quality Control BuildingSources

Established a subsidiary, Asuka Animal Health Co., Ltd.Sources

Launched treatment drug for endometriosis, uterine fibroids, and prostate cancer, 'Lupron Acetate Injection Kit Asuka'.Sources

Launched antihypertensive drug 'Candesartan Tablets Asuka'.Sources

Asuka Pharmaceutical celebrates its 10th anniversary.Sources

Transferred sales and manufacturing approval of antithyroid drugs 'Mercazole Tablets', 'Mercazole Injections', and 'Propylthiouracil Tablets' from Chugai Pharmaceutical Co., Ltd.Sources

Completion of Iwaki Factory and Fourth Formulation Building.Sources

Launched infertility treatment drug 'Luteum Vaginal Suppositories'.Sources

Launched hepatic encephalopathy treatment drug 'Refximia Tablets'.Sources

Invested jointly with Omnicare Drugs India Private Limited in NeoASKA Pharma Private Limited in India.Sources

Launched dysmenorrhea treatment drug 'Frewell Combination Tablets LD/ULD Asuka'.Sources

Launched uterine fibroid treatment drug 'Lermina Tablets' (additional indication for endometriosis in December 2021).Sources

Transferred sales and manufacturing approval of uterine contraction suppressant 'Magcent Injections', 'Magcent Syringe Injections', and eclampsia suppression and treatment drug 'Magnesol for Injection' from Toa Pharmaceutical Industry Co., Ltd.Sources

Relocated Kawasaki Research Institute to Shonan Health Innovation Park: Started as 'Shonan Research Institute'.Sources

Established 'Women’s Health Lab Mint : + : '.Sources

Launched thyroid drug 'Thyroxin S Injection'.Sources

Vietnam's 'Ha Tay Pharmaceutical Joint Stock Company' becomes an equity-method affiliate.Sources

Established Asuka Pharmaceutical Holdings Co., Ltd.Sources

Established an international office in London, UK.Sources

Yamaguchi Sōdai appointed as President.Sources

Launched dysmenorrhea treatment drug 'Droethy Combination Tablets Asuka'.Sources

Launch of oral contraceptive 'Sundinda Tablets 28'Sources

§07

News

63 ARTICLES

Results Published for PMS/PMDD Therapeutic App TrialSources

ASKA Pharmaceutical announced that results of a specified clinical trial of a therapeutic app for premenstrual syndrome and premenstrual dysphoric disorder have been published on Japan’s jRCT registry. The trial was conducted in collaboration with SUSMED and Professor Mariko Ogawa of Fukushima Medical University.

Clinical Study Results of an App for Treating Premenstrual Symptoms PublishedSources

Asuka Pharmaceutical and Sasemed, in collaboration with Professor Mariko Ogawa of Fukushima Prefectural Medical University, conducted a specific clinical study on a therapeutic app targeting patients with premenstrual syndrome or premenstrual dysphoric disorder. The study results were published on the Clinical Research Information Service (jRCT). This does not affect Asuka Pharmaceutical's fiscal year ending March 2027 performance.

Experience-Based Menstrual Seminar "Menstrual Lab®" for Sony Network Communications EmployeesSources

Asuka Pharmaceutical Co., Ltd. and Asai Co., Ltd. conducted a seminar for Sony Network Communications employees, where participants learned about menstrual health issues such as menstruation and PMS through a training video supervised by obstetricians and gynecologists and an experiential session using artificial menstrual blood. Participants reported re-evaluating their own symptoms and gaining new insights from others' experiences.

Training Service for Managers Supporting Fertility Treatment LaunchedSources

Asuka Pharmaceutical Co., Ltd. and Rupan Consulting launched the training service "Work Health Palette (Fertility Treatment Edition)" on November 10, 2026, focusing on supporting the balance between fertility treatment and work. The service primarily targets managers, providing a structured program to learn about the medical basics of fertility treatment, workplace responses, and career support.

Workstyle Reform for Women! Menstrual Comfort Project Media SeminarSources

Aska Pharmaceutical Medical Co., Ltd., in cooperation with Fuji Pharma Co., Ltd., will hold a media seminar on December 4, 2026, as part of the “Workstyle Reform for Women! Menstrual Comfort Project,” organized by the Nikkei BP Research Institute. The seminar will be held in a hybrid format, with both in-person attendance and a live stream, and will explain to members of the press the impact of menstrual symptoms on work and the importance of treatment and creating supportive environments.

ASKA Pharmaceutical selected for AMED’s GRiT programSources

ASKA Pharmaceutical has been selected for the 2026 fiscal year Grant Program for Research and Development on Rare and Intractable Diseases (GRiT), sponsored by AMED (Japan Agency for Medical Research and Development). This selection marks an important step toward advancing the company’s investigational drug AKP-021 into a Phase II clinical trial in patients with IC/BPS.

AKP-021 Development Selected for AMED GRiT ProjectSources

The research and development challenge "Verification of efficacy and safety assessment for IC/BPS patients using AKP-021" by Asuka Pharmaceutical has been selected for AMED's 2026 fiscal year Global Research and Development Support Project for Rare and Intractable Diseases (GRiT). We will advance development toward a Phase II clinical trial targeting IC/BPS patients. In this public solicitation, 25 projects were submitted and 8 were selected.

ASKA Pharmaceutical enters agreement for Wellnara® manufacturing and marketing rightsSources

TOKYO, November 4, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. announced that its subsidiary, ASKA Pharmaceutical Co., Ltd., has entered into an agreement to transfer the manufacturing and marketing authorization and related marketing rights in Japan for Wellnara® Combination Tablets, an oral estrogen therapy. The agreement will enable the subsidiary to manufacture and market the product within Japan.

ASKA Pharma Launches Drospirenone TrialSources

ASKA Pharmaceutical Holdings announced the start of a Phase III clinical trial in Japan for its drospirenone formulation LPRI-CF113, targeting patients with dysmenorrhea. The trial, named PROFILE-D, will compare the new drug against existing progestin therapies in a randomized head‑to‑head design. The study aims to evaluate efficacy and safety in the obstetrics and gynecology field.

ASKA Pharma Licenses MHB018A for TEDSources

ASKA Pharmaceutical Holdings Co., Ltd. announced that it has entered into a license agreement for MHB018A, a therapeutic candidate for thyroid eye disease (TED). The agreement positions ASKA Pharma to advance the development and potential commercialization of MHB018A for patients with TED.

§08

Public records

GOV
National Tax Agency basic information5020001066661
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社あすか製薬メディカル
Trade name (kana)
アスカセイヤクメディカル
Name in English
Corporation type
301
Address
〒251-0012 神奈川県藤沢市村岡東2丁目26-1湘南ヘルスイノベーションパーク内
Postal code
2510012
Prefecture code
14
City code
205
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2020-04-07
Change date
2020-04-02
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2779244
METI gBizINFO5020001066661
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
5020001066661
Trade name
株式会社あすか製薬メディカル
Trade name (kana)
アスカセイヤクメディカル
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
神奈川県藤沢市村岡東2丁目26-1湘南ヘルスイノベーションパーク内
Postal code
2510012
Prefecture
神奈川県
Prefecture code
14
City or district
藤沢市
City code
205
Street address
村岡東2丁目26-1湘南ヘルスイノベーションパーク内
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役 堀 英紀
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
1991-05-28
Unified government qualification - grade
||C|
Unified government qualification - business items
303
Update date
2020-04-07
Key information
5020001066661
§09

Sources & updates

SOURCES
↑